<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">541</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2023-10-2-58-69</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The diagnostic and therapeutic potential of exosomal proteins in breast cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Диагностический и терапевтический потенциал белков экзосом при раке молочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5369-397X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shefer</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Шефер</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>8 Akademika Lavrent’eva Prospekt, Novosibirsk 630090; 2 Pirogova St., Novosibirsk 630090</p></bio><bio xml:lang="ru"><p>630090 Новосибирск, проспект Академика Лаврентьева, 8; 630090 Новосибирск, ул. Пирогова, 2</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0390-6580</contrib-id><name-alternatives><name xml:lang="en"><surname>Frik</surname><given-names>Ya. A.</given-names></name><name xml:lang="ru"><surname>Фрик</surname><given-names>Я. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>2 Pirogova St., Novosibirsk 630090</p></bio><bio xml:lang="ru"><p>630090 Новосибирск, ул. Пирогова, 2</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7774-943X</contrib-id><name-alternatives><name xml:lang="en"><surname>Tamkovich</surname><given-names>S. N.</given-names></name><name xml:lang="ru"><surname>Тамкович</surname><given-names>С. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Svetlana N. Tamkovich.</p><p>8 Akademika Lavrent’eva Prospekt, Novosibirsk 630090; 2 Pirogova St., Novosibirsk 630090</p></bio><bio xml:lang="ru"><p>Тамкович Светлана Николаевна.</p><p>630090 Новосибирск, проспект Академика Лаврентьева, 8; 630090 Новосибирск, ул. Пирогова, 2</p></bio><email>s.tamkovich@g.nsu.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Novosibirsk State University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2023</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>58</fpage><lpage>69</lpage><history><date date-type="received" iso-8601-date="2023-02-13"><day>13</day><month>02</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-07-10"><day>10</day><month>07</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Shefer A.A., Frik Y.A., Tamkovich S.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Шефер А.А., Фрик Я.А., Тамкович С.Н.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Shefer A.A., Frik Y.A., Tamkovich S.N.</copyright-holder><copyright-holder xml:lang="ru">Шефер А.А., Фрик Я.А., Тамкович С.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/541">https://umo.abvpress.ru/jour/article/view/541</self-uri><abstract xml:lang="en"><p>Exosomes are membrane vesicles 30–150 nm in size released by cells upon fusion of multivesicular bodies with the plasma membrane. A distinctive feature of these vesicles is the presence of the surface tetraspanins CD9, CD63, and CD81. The Rab family of small GTPases, including Rab27A and Rab27B, controls various steps in exosome release, including transport of multivesicular bodies and fusion of the multivesicular body to the plasma membrane. It is commonly accepted to date that exosomes are the main carriers of information between cells under physiological conditions, such as mammary development and lactation, and under pathological conditions, such as breast cancer. This review considers the peculiarities of exosome formation, secretion and transport, their composition and role in normal and breast cancer, as well as the prospects for using these vesicles to develop early non-invasive diagnostics and improve the effectiveness of anti-tumor therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Экзосомы представляют собой мембранные везикулы размером 30–150 нм, которые высвобождаются клетками при слиянии мультивезикулярных телец с плазматической мембраной. Отличительной чертой этих везикул является наличие в них поверхностных тетраспанинов CD9, CD63 и CD81. Семейство малых ГТфаз Rab, включая Rab27A и Rab27B, контролирует различные этапы высвобождения экзосом, в том числе транспорт мультивезикулярных телец и слияние мультивезикулярного тельца с плазматической мембраной. На сегодняшний день принято считать экзосомы основными переносчиками информации между клетками в физиологических  условиях, таких как развитие молочной железы и лактация, и при патологии, например при раке молочной железы. в обзоре рассмотрены особенности формирования, секреции и транспорта экзосом, их состав и роль в норме и при раке молочной железы, а также перспективы использования этих везикул для разработки ранней неинвазивной диагностики и повышения эффективности противоопухолевой терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>exosomes</kwd><kwd>breast cancer</kwd><kwd>breast cancer diagnosis</kwd><kwd>breast cancer therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>экзосомы</kwd><kwd>рак молочной железы</kwd><kwd>диагностика рака молочной железы</kwd><kwd>терапия рака молочной железы</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was supported by the Russian state budget project via the Ministry of Education and Science of Russia No. 121030200173-6 “Diagnostics and therapy of oncological diseases”.</funding-statement><funding-statement xml:lang="ru">Работа выполнена в рамках проекта базового бюджетного финансирования Минобрнауки России № 121030200173-6 «Диагностика и терапия онкологических заболеваний».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Tamkovich S.N., Yunusova N.V., Stakheeva M.N. Isolation and characterization of plasma exosomes of patients with breast cancer and colorectal cancer. Biomeditsinskaya khimiya = Biomedical Chemistry 2017;165–9. (In Russ.). DOI: 10.18097/PBMC20176302165</mixed-citation><mixed-citation xml:lang="ru">Тамкович С.Н., Юнусова Н.В., Стахеева М.Н. Выделение и характеризация экзосом плазмы крови больных раком молочной железы и колоректальным раком. Биомедицинская химия 2017;165–9. DOI: 10.18097/PBMC20176302165</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Schaefer A.A. Exosomes of breast carcinoma: assessment of tumor potential in the in vivo system and identification of proteins involved in tumor dissemination. Bachelor’s final qualifying work. Novosibirsk, 2022. 80 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Шефер А.А. Экзосомы карциномы молочной железы: оценка опухолевого потенциала в системе in vivo и идентификация белков, вовлеченных в опухолевую диссеминацию. Выпускная квалификационная работа бакалавра. Новосибирск, 2022. 80 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Théry C., Witwer K.W., Aikawa E. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7(1):1535750. DOI: 10.1080/20013078.2018.1535750</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kok V.C., Yu C.-C. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int J Nanomedicine 2020;15:8019–36. DOI: 10.2147/IJN.S272378</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Triantafyllou A., Gazouli M., Theodoropoulos C. et al. Exosomes in breast cancer management: where do we stand? A literature review. Biol Cell 2022;114(4):109–22. DOI: 10.1111/boc.202100081</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 2016;126(4):1208–15. DOI: 10.1172/JCI81135</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bebelman M., Smith M., Pegtel M. et al. Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther 2018;188:1–11. DOI: 10.1016/j.pharmthera.2018.02.013</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Tenchov R., Sasso M.J., Wang X. et al. Exosomes – nature’s lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano 2022;16(11):17802–46. DOI: 10.1021/acsnano.2c08774</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Huotari J., Helenius A. Endosome maturation. EMBO J 2011;30(17):3481–500. DOI: 10.1038/emboj.2011.286</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ren X., Hurley J.H. VHS domains of ESCRT-0 cooperate in high-avidity binding to polyubiquitinated cargo. EMBO J 2010;29(6):1045–54. DOI: 10.1038/emboj.2010.6</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Wollert T., Yang D., Ren X. et al. The ESCRT machinery at a glance. J Cell Sci 2009;122(Pt. 13):2163–6. DOI: 10.1242/jcs.029884</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ostrowski M., Carmo B.N., Krumeich S. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010;12(1):19–30. DOI: 10.1038/ncb2000</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wei D., Zhan W., Gao Y. et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res 2021;31(7): 157–77. DOI: 10.1038/s41422-020-00409-1</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Trajkovich K., Hsu C., Chiantia S. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008;319(5867):1244–7. DOI: 10.1126/science.1153124</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nonaka T., Wong D.T.W. Saliva-exosomics in cancer: molecular characterization of cancer-derived exosomes in saliva. Enzymes 2017;42:125–51. DOI: 10.1016/bs.enz.2017.08.002</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhang J., Lui S.-C., Luo X.-H. et al. Exosomal long noncoding RNAs are differentially expressed in the cervicovaginal lavage samples of cervical cancer patients. J Clin Lab Anal 2016;30(6):1116–21. DOI: 10.1002/jcla.21990</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Tamkovich S.N., Tutanov O.S., Laktionov P.P. Exosomes: generation, structure, transport, biological activity, and diagnostic application. Biochem Suppl Ser A Membr Cell Biol 2016;10(3):163–73. DOI: 10.1134/S1990747816020112</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Grigorieva A.E., Tamkovich S.N., Eremina A.V. et al. Exosomes of lacrimal fluid of healthy people: isolation, identification and characterization. Biomeditsinskaya khimiya = Biomedical Chemistry 2016;62(1):99–106. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Григорьева А.Е., Тамкович С.Н., Еремина А.В. и др. Экзосомы слезной жидкости здоровых людей: выделение, идентификация и характеризация. Биомедицинская химия 2016;62(1):99–106.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Kim K.-U., Kim W.-H., Jeong C.-H. et al. More than nutrition: therapeutic potential of breast milk-derived exosomes in cancer. Int J Mol Sci 2020;21(19):7327. DOI: 10.3390/ijms21197327</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Dong X., Bai X., Ni J. et al. Exosomes and breast cancer drug resistance. Cell Death Dis 2020;11(11):987. DOI: 10.1038/s41419-020-03189-z</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Tamkovich S., Tutanov O., Efimenko A. et al. Blood circulating exosomes contain distinguishable fractions of free and cell-surface-associated vesicles. Curr Mol Med 2019;19(4):273–85. DOI: 10.2174/1566524019666190314120532</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bonifácio V.D.B. Ovarian cancer biomarkers: moving forward in early detection. Adv Exp Med Biol 2020;1219:355–63. DOI: 10.1007/978-3-030-34025-4_18</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kuang Y., Peng C., Dong Y. et al. NADH dehydrogenase subunit 1/4/5 promotes survival of acute myeloid leukemia by mediating specific oxidative phosphorylation. Mol Med Rep 2022;25(6):195. DOI: 10.3892/mmr.2022.12711</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Justo B.L., Jasiulionis M.G. Characteristics of TIMP1, CD63, and β1-integrin and the functional impact of their interaction in cancer. Int J Mol Sci 2021;22(17):9319. DOI: 10.3390/ijms22179319</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Qin Y., Shembrey C., Smith J. et al. Laminin 521 enhances self-renewal via STAT3 activation and promotes tumor progression in colorectal cancer. Cancer Letters 2020;476:161–9. DOI: 10.1016/j.canlet.2020.02.026</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Zhang T., Sun L., Hao Y. et al. ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1. Nat Cancer 2022;3(1):75–89. DOI: 10.1038/s43018-021-00299-1</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Hong J., Guo F., Lu S.-Y. et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut 2021;70(11):2123–37. DOI: 10.1136/gutjnl-2020-322780</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Li H.-J., Ke F.-Y., Lin C.-C. et al. ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-to-mesenchymal transition. Cancer Res 2021;81(15):4094–09. DOI: 10.1158/0008-5472.CAN-20-3543</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Park M.K., Zhang L., Min K.-W. et al. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab 2021;33(12):2380–97. DOI: 10.1016/j.cmet.2021.11.011</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Lan Z., Yao X., Sun K. et al. The Interaction between lncRNA SNHG6 and hnRNPA1 contributes to the growth of colorectal cancer by enhancing aerobic glycolysis through the regulation of alternative splicing of PKM. Front Oncol 2020;10:363. DOI: 10.3389/fonc.2020.00363</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Nie H., Ju H., Fan J. et al. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun 2020;11(1):36. DOI: 10.1038/s41467-019-13601-8</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Huang C., Shen Q., Song G. et al. Downregulation of PARVA promotes metastasis by modulating integrin-linked kinase activity and regulating MAPK/ERK and MLC2 signaling in prostate cancer. Transl Androl Urol 2021;10(2):915–28. DOI: 10.21037/tau-21-108</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Tong X.-Y., Yang X.-Z., Gao S.-Q. et al. Regulating effect of cytochrome b5 overexpression on human breast cancer cells. Molecules 2022;27(14):4556. DOI: 10.3390/molecules27144556</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Laulagnier K., Motta C., Hamdi S. et al. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 2004;380(Pt. 1): 161–71. DOI: 10.1042/BJ20031594</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Choi D.-S., Kim D.-K., Kim Y.-K. et al. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 2013;13(10–11):1554–71. DOI: 10.1002/pmic.201200329</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Llorente A., Skotland T., Sylvänne T. et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta 2013;1831(7):1302–9. DOI: 10.1016/j.bbalip.2013.04.011</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Carayon K., Chaoui K., Ronzier E. et al. Proteolipidic composition of exosomes changes during reticulocyte maturation. J Biol Chem 2011;286(39):34426–39. DOI: 10.1074/jbc.M111.257444</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Beloribi S., Ristorcelli E., Breuzard G. et al. Exosomal lipids impact notch signaling and induce death of human pancreatic tumoral SOJ-6 cells. PLoS One 2012;7(10):e47480. DOI: 10.1371/journal.pone.0047480</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Wang G., Dinkins M., He Q. et al. Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). J Biol Chem 2012;287(25):21384–95. DOI: 10.1074/jbc.M112.340513</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906. DOI: 10.1055/s-0030-1267043</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Balaj L., Lessard R., Cho Y.-J. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011;2:180. DOI: 10.1038/ncomms1180</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Tutanov O., Shtam T., Tupkin A. et al. Blood plasma exosomes contain circulating DNA in their crown. Diagnostics (Basel) 2022;12(4):854. DOI: 10.3390/diagnostics12040854</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Xie Y., Dang W., Zhang S. et al. The role of exosomal noncoding RNAs in cancer. Mol Cancer 2019;18(1):37. DOI: 10.1186/s12943-019-0984-4</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Eldh M., Ekstrom K., Valadi H. et al. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One 2010;5(12):e15353. DOI: 10.1371/journal.pone.0015353</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>O’Brien K., Rani S., Corcoran C. et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 2013;49(8):1845–59. DOI: 10.1016/j.ejca.2013.01.017</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Ding G., Zhou L., Qian Y. et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget 2015;6(30):29877–88. DOI: 10.18632/oncotarget.4924</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Ying X., Wu Q., Wu X. et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget 2016;7(28):43076–87. DOI: 10.18632/oncotarget.9246</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011;71(11):3792–801. DOI: 10.1158/0008-5472.CAN-10-4455</mixed-citation></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Bayerli O.A., Gareev I.F., Pavlov V.N. Exosomal long non-coding RNAs as biomarkers and therapeutic targets in cancer. Kreativnaya khirurgiya i onkologiya = Creative Surgery and Oncology 2019;9(4):297–304. (In Russ.). DOI: 10.24060/2076-3093-2019-9-4-297-304</mixed-citation><mixed-citation xml:lang="ru">Бейерли О.А., Гареев И.Ф., Павлов В.Н. Экзосомальные длинные некодирующие РНК как биомаркеры и терапевтические мишени при раке. Креативная хирургия и онкология 2019;9(4):297–304. DOI: 10.24060/2076-3093-2019-9-4-297-304</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><mixed-citation>Harris D.A., Patel S.H., Gucek M. et al. Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS One 2015;10(3):e0117495. DOI: 10.1371/journal.pone.0117495</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Boucheix C., Duc G.H., Jasmin C. et al. Tetraspanins and malignancy. Expert Rev Mol Med 2001;2001:1–17. DOI: 10.1017/S1462399401002381</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Li K., Liu T., Chen J. et al. Survivin in breast cancer-derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis. J Biol Chem 2020;295(40):13737–52. DOI: 10.1074/jbc.RA120.013805</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Katoh M., Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med 2020;45(2):279–97. DOI: 10.3892/ijmm.2019.4418</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Yuan X., Qian N., Ling S. et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 2021;11(3):1429–45. DOI: 10.7150/thno.45351</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Patwardhan S., Mahadik P., Shetty O. et al. ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1. Biomaterials 2021;279:121185. DOI: 10.1016/j.biomaterials.2021.121185</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Jordan K.R., Hall J.K., Schedin T. et al. Extracellular vesicles from young women’s breast cancer patients drive increased invasion of non-malignant cells via the focal adhesion kinase pathway: a proteomic approach. Breast Cancer Res 2020;22(1):128. DOI: 10.1186/s13058-020-01363-x</mixed-citation></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Samsonov R.B., Kovalenko I.M., Vasiliev D.A. Stimulation of metastatic activity of breast cancer cells by plasma exosomes. Rossiiskii bioterapevticheskii zhurnal = Russian Biotherapeutic Journal 2016;15(2):6–15. (In Russ.). DOI: 10.17650/1726-9784-2016-15-2-6-15</mixed-citation><mixed-citation xml:lang="ru">Самсонов Р.Б., Коваленко И.М., Васильев Д.А. Стимуляция метастатической активности клеток рака молочной железы экзосомами плазмы. Российский биотерапевтический журнал 2016;15(2):6–15. DOI: 10.17650/1726-9784-2016-15-2-6-15</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><mixed-citation>Ham S., Lima L.G., Chai E.P.Z. et al. Breast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 signaling. Front Immunol 2018;9:871. DOI: 10.3389/fimmu.2018.00871</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Mengos A.E., Gastineau D.A., Gustafson M.P. The CD14+HLA-DRlo/neg monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy. Front Immunol 2019;10:1147. DOI: 10.3389/fimmu.2019.01147</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Contini P., Ghio M., Merlo A. et al. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is fas ligand/fas mediated: evidence for the involvement of p56 lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for NF-κB and NF-AT nuclear translocation. J Immunol 2005;175(11):7244–54. DOI: 10.4049/jimmunol.175.11.7244</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Tian X., Shen H., Li Z. et al. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol 2019;12(1):84. DOI: 10.1186/s13045-019-0772-z</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Farhood B., Najafi M., Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 2019;234(6):8509–21. DOI: 10.1002/jcp.27782</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Cameron D., Piccart-Gebhart M.J., Gelber R.D. et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017;389(10075):1195–205. DOI: 10.1016/S0140-6736(16)32616-2</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Ciravolo V., Huber V., Ghedind G.C. et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012;227(2):658–67. DOI: 10.1002/jcp.22773</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Semina S.E., Scherbakov A.M., Vnukova A.A. et al. Exosome-mediated transfer of cancer cell resistance to antiestrogen drugs. Molecules 2018;23(4):829. DOI: 10.3390/molecules23040829</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Andreeva O.E., Sorokin D.V., Mikhaevich E.I. et al. Towards unravelling the role of ERα-targeting miRNAs in the exosome-mediated transferring of the hormone resistance. Molecules 2021;26(21):6661. DOI: 10.3390/molecules26216661</mixed-citation></ref><ref id="B67"><label>67.</label><citation-alternatives><mixed-citation xml:lang="en">Semina S.E., Rudenskaya E.A., Mittenberg A.G. et al. Exosomes and development of cancer cell resistance to metformin: pilot study. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2017;4(3):92–8. (In Russ.). DOI: 10.17650/2313-805X-2017-4-3-92-98</mixed-citation><mixed-citation xml:lang="ru">Семина С.Е., Руденская Е.А., Миттенберг А.Г. и др. Экзосомы и развитие резистентности опухолевых клеток к метформину: пилотное исследование. Успехи молекулярной онкологии 2017;4(3):92–8. DOI: 10.17650/2313-805X-2017-4-3-92-98</mixed-citation></citation-alternatives></ref><ref id="B68"><label>68.</label><mixed-citation>Chanteloup G., Cordonnier M., Isambert N. et al. Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study. J Extracell Vesicles 2020;9(1):1766192. DOI: 10.1080/20013078.2020.1766192</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Melo S.A., Luecke L.B., Kahlert C. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523(7559):177–82. DOI: 10.1038/nature14581</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Wang X., Zhong W., Bu J. et al. Exosomal protein CD82 as a diagnostic biomarker for precision medicine for breast cancer. Mol Carcinog 2019;58(5):674–85. DOI: 10.1002/mc.22960</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Tutanov O., Orlova E., Proskura K. et al. Proteomic analysis of blood exosomes from healthy females and breast cancer patients reveals an association between different exosomal bioactivity on non-tumorigenic epithelial cell and breast cancer cell migration in vitro. Biomolecules 2020;10(4):495. DOI: 10.3390/biom10040495</mixed-citation></ref><ref id="B72"><label>72.</label><citation-alternatives><mixed-citation xml:lang="en">Tumanov O.S., Bakakina Yu.S., Proskura K.V. et al. Search for proteomic markers of breast cancer in the composition of total blood exosomes. Sibirskij onkologicheskij zhurnal = Siberian Journal of Oncology 2020;19(2):49–61. DOI: 10.21294/1814-4861-2020-19-2-49-61</mixed-citation><mixed-citation xml:lang="ru">Тутанов О.С., Бакакина Ю.С., Проскура К.В. и др. Поиск протеомных маркеров рака молочной железы в составе суммарных экзосом крови. Сибирский онкологический журнал 2020;19(2):49–61. DOI: 10.21294/1814-4861-2020-19-2-49-61</mixed-citation></citation-alternatives></ref><ref id="B73"><label>73.</label><mixed-citation>Sipeng L., Xinya L., Hao P. et al. Proteomic landscape of exosomes reveals the functional contributions of CD151 in triple-negative breast cancer. Mol Cell Proteomics 2021;20:100121. DOI: 13.1016/j.mcpro.2021.100121</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Vardaki I., Ceder S., Rutishauser D. et al. Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. Oncotarget 2016;7(46):74966–78. DOI: 10.18632/oncotarget.11663</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Rupp A.-K., Rupp C., Keller S. et al. Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecol Oncol 2011;122(2):437–46. DOI: 10.1016/j.ygyno.2011.04.035</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Hoshino A., Kim S.H., Bojman L. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 2020;182(4):1044–61.e18. DOI: 10.1016/j.cell.2020.07.009</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Toth B., Nieuwland R., Liebhardt S. et al. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 2008;28(2A):1107–12.</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Sancho-Albero M., Navascuеs N., Mendoza G. et al. Exosome origin determines cell targeting and the transfer of therapeutic nanoparticles towards target cells. J Nanobitechnol 2019;7(1):16. DOI: 10.1186/s12951-018-0437-z</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Hazan-Halevy I., Rosenblum D., Weinstein S. et al. Cell-specific uptake of mantle cell lymphoma derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Lett 2015;364(1):59–69. DOI: 10.1016/j.canlet.2015.04.026</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Yue S., Ye X., Zhou T. et al. PGRN-/-TAMs-derived exosomes inhibit breast cancer cell invasion and migration and its mechanism exploration. Life Sci 2021;264:118687. DOI: 10.1016/j.lfs.2020.118687</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>Gong C., Tian J., Wang Z. et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnology 2019;17(1):93. DOI: 10.1186/s12951-019-0526-7</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Yu M., Gai C., Li Z. et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci 2019;110(10)3173–82. DOI: 10.1111/cas.14181</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Weaver W. J., Zhang J., Rojas J. et al. The application of exosomes in the treatment of triple-negative breast cancer. Front Mol Biosci 2022;9:1022725. DOI: 10.3389/fmolb.2022.1022725</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Vakhshiteh F., Atyabi F., Ostad N.S. Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy. Int J Nanomedicine 2019;14:2847–59. DOI: 10.2147/IJN.S200036</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Goh J.W., Zou S., Lee K.C. et al. EXOPLEXs: chimeric drug delivery platform from the fusion of cell-derived nanovesicles and liposomes. Biomacromolecules 2018;19(1):22–30. DOI: 10.1021/acs.biomac.7b01176</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Katakpwski M., Buller B., Zheng X. et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 2013;335(1):201–4. DOI: 10.1016/j.canlet.2013.02.019</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation>Bolukbasi F.M., Mizrak A., Ozdener B.G. et al. miR-1289 and “Zipcode”-like sequence enrich mRNAs in microvesicles. Mol Ther Nucleic Acids 2012;1(2):e10. DOI: 10.1038/mtna.2011.2</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation>Riazifar M., Pone J.E., Lotvall J. et al. Stem cell extracellular vesicles: extended messages of regeneration. Annu Rev Pharmacol Toxicol 2017;57:125–54. DOI: 10.1146/annurev-pharmtox-061616-030146</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Tian Y., Li S., Song J. et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014;11(3):2383–90. DOI: 10.1016/j.biomaterials.2013.11.083</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Naseri Z., Oskuee K.R., Jaafari R.M. et al. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nano-medicine 2018;13:7727–47. DOI: 10.2147/IJN.S182384</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Hung E.M., Leonard N.J. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem 2015;290(13):8166–72. DOI: 10.1074/jbc.M114.621383</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Kosaka N., Yoshioka Y., Tominaga N. et al. Dark side of the exosome: the role of the exosome in cancer metastasis and targeting the exosome as a strategy for cancer therapy. Future Oncol 2014;10(4):671–81. DOI: 10.2217/fon.13.222</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Nishida-Aoki N., Tominaga N., Takeshita F. et al. Disruption of circulating extracellular vesicles as a novel therapeutic strategy against cancer metastasis. Mol Ther 2017;25(1):181–91. DOI: 10.1016/j.ymthe.2016.10.009</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Baglio R.S., Largerweij T., Perez-Lanzon M. et al. Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression. Clin Cancer Res 2017;23(14):3721–33. DOI: 10.1158/1078-0432.CCR-16-2726</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Santos M.F., Rappa G., Karbanova J. et al. Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins. J Cell Mol Med 2019;23(6):4408–21. DOI: 10.1111/jcmm.14334</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Wei Z., Chen Z., Zhao Y. et al. Mononuclear phagocyte system blockade using extracellular vesicles modified with CD47 on membrane surface for myocardial infarction reperfusion injury treatment. Biomaterials 2021;275:121000. DOI: 10.1016/j.biomaterials.2021.121000</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Tominaga N. Anti-cancer role and therapeutic potential of extracellular vesicles. Cancers (Basel) 2021;13(24):6303. DOI: 10.3390/cancers13246303</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Roma-Rodrigues C., Fernandes A.R., Baptista P.V. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed Res Int 2014;2014:179486. DOI: 10.1155/2014/179486</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Alimirzaie S., Bagherzadeh M., Akbari M.R. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet 2019;95(6):643–60. DOI: 10.1111/cge.13514</mixed-citation></ref></ref-list></back></article>
